Portfoliotracker

Unicycive Therapeutics, Inc.

UNCY · NASDAQCM · Healthcare Biotechnology 17/100 E

3,700 $
▲ +0,150 (+4,23 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 14:57
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score17 / 100 Market cap96,4 mil. $ P/E– Forward P/E2,5 P/S– P/B1,8 EV/EBITDA– Dividend yield– FCF yield-28,90 % EPS-1,72 $ Net margin0,0 % Return on equity-101,1 % Beta1,86 Debt / equity0,01
52-week range 3,33 to 8,74
3-month average volume0,9 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.

Employees
21
Country
United States
Fiscal year end
31. 12.
Data since
12. 7. 2021

Explore further

Similar companies PALI

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account